MGI Tech Co., Ltd., a leader in developing innovative tools and technologies for life sciences, has launched the DNBSEQ-G400RS FluoXpert in the APAC region, introducing it at Medlab Asia & Asia Health 2024. This cutting-edge platform integrates high-throughput sequencing with multiplex immunofluorescence (mIF) staining, positioning itself as a multifunctional sequencer capable of in vivo spatial protein detection.
"We are excited to present our DNBSEQ-G400RS FluoXpert to international customers and partners", said Dr. Roy Tan, General Manager of MGI Asia Pacific. "Recent developments in pathology highlight trends toward automation and multiplexed spatial phenotyping. The DNBSEQ-G400RS FluoXpert is a fully automated high-plex multi-omics instrument combining DNA/RNA and protein analysis in one, offering a powerful and cost-effective upgrade from conventional pathology and spatial proteomics tools".
The new sequencer holds significant potential for cancers with high somatic mutations, which are prevalent in the APAC region and known to be more responsive to immunotherapies. "The G400 sequencer, globally recognized for its extensive use, has consistently offered an economical platform for professional sequencing analysis", stated Dr. Meng Yang, Assistant General Manager and VP of MGI R&D. "With the introduction of our gradable multiplex spatial phenotyping tool, we aim to revolutionize spatial biomarker discovery and immunotherapeutic research".
DNBSEQ-G400RS FluoXpert leverages MGI's DNBSEQ technology alongside efficient mIF staining technology. With a simple software upgrade, users can transform the DNBSEQ-G400RS into the FluoXpert model, enabling them to obtain both molecular and cellular morphological information on the same platform. This ability to switch seamlessly between sequencing and staining tasks enhances efficiency and broadens the instrument's applicability in tumor classification, disease prognosis, tissue microenvironment analysis, and more.
Designed with principles of systemization and modularization, the DNBSEQ-G400RS FluoXpert features optimized hardware, state-of-the-art biochemistry, and innovative software for a comprehensive multi-omics experience. The benchtop sequencer is equipped with advanced optical, mechanical, fluidics, and electrical systems, facilitating a more rapid and streamlined sequencing process.
The FluoXpert platform is complemented by an easy-to-use and flexible mIF reagent set, compatible with both frozen tissue and FFPE samples, as well as off-the-shelf antibodies, eliminating the need for complex conjugation processes. Available in standard and customized options, the reagent set includes an autofluorescence quenching reagent and mild elution technology, ensuring low residual signal and optimal antigen preservation.
Additionally, the FluoXpert program supports fully automated fluorescence staining, high-resolution scanning, and imaging. It features customizable protocols, real-time image visualization, antibody library management, and independent wash and elution. The resulting images boast high quality with seamless stitching and 20x subcellular resolution (360 nm per pixel). Efficient fluid exchange and mild elution reagents ensure the sample tissue remains intact despite multiple staining cycles, guaranteeing robust reproducibility.
The DNBSEQ-G400RS FluoXpert operates at 50 minutes per cycle, tripling the speed of conventional manual staining and imaging. Its optimal throughput ranges between 20 to 40 sections per week using the standard 6-plex staining kit, with the highest throughput reaching up to 140 sections per week. Comparative results show no significant difference between mIF and the gold standard IHC, highlighting its exceptional performance in spatial protein identification and proteomics research.
MGI's vision to maximize the DNBSEQ-G400RS sequencer's capabilities extends through the 'What If G400 Developer Program', Launched during the opening of MGI's European headquarters in Berlin, the initiative encourages global researchers to develop and implement customized workflows for spatial transcriptomics, multiplex immunofluorescence (mIF), and other multi-omics analyses on the DNBSEQ-G400RS. Researchers in the APAC region, especially in Australia, Singapore, and Japan, can apply for the program until August 30, 2024.